{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T22:40:19Z","timestamp":1688078419506},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin. Drug Investig."],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1007\/bf03256916","type":"journal-article","created":{"date-parts":[[2013,3,3]],"date-time":"2013-03-03T01:37:04Z","timestamp":1362274624000},"page":"759-767","source":"Crossref","is-referenced-by-count":1,"title":["Morphological and Metabolic Components of Lipodystrophy in Various Nevirapine-Based Highly Active Antiretroviral Therapy (HAART) Regimens"],"prefix":"10.1007","volume":"31","author":[{"given":"Giovanni","family":"Guaraldi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Zona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriella","family":"Orlando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"Carli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Stentarelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kety","family":"Luzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Garlassi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianna","family":"Menozzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pietro","family":"Bagni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fulvio","family":"Adorni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,8,28]]},"reference":[{"key":"BF03256916_CR1","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1097\/01.aids.0000171405.46113.bf","volume":"19","author":"C. Fisac","year":"2005","unstructured":"Fisac C, Fumero E, Crespo M, et al. Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine. AIDS 2005; 19: 917\u201325","journal-title":"AIDS"},{"key":"BF03256916_CR2","doi-asserted-by":"crossref","first-page":"5186","DOI":"10.1210\/jc.2002-021830","volume":"88","author":"C. Fisac","year":"2003","unstructured":"Fisac C, Virgili N, Ferrer E, et al. A comparison of the effects of nevirapine and nelfinavir on metabolism and body habitus in antiretroviral-naive human immunodeficiency virus-infected patients: a randomized controlled study. J Clin Endocrinol Metab 2003; 88: 5186\u201392","journal-title":"J Clin Endocrinol Metab"},{"key":"BF03256916_CR3","doi-asserted-by":"crossref","first-page":"e5647","DOI":"10.1371\/journal.pone.0005647","volume":"4","author":"M.G. Vonderen van","year":"2009","unstructured":"van Vonderen MG, van Agtmael MA, Hassink EA, et al. Zidovudine\/lamivudine for HIV-1 infection contributes to limb fat loss. PLoS One 2009; 4: e5647","journal-title":"PLoS One"},{"key":"BF03256916_CR4","unstructured":"DHSS. Panel on Antiretroviral Guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services; 2008 Nov 3: 1\u2013139"},{"key":"BF03256916_CR5","unstructured":"EACS. European AIDS Clinical Society (EACS) guidelines 2008. Guidelines for the clinical management and treatment of HIV infected adults in Europe. Version 4: Paris, October 2008"},{"key":"BF03256916_CR6","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1089\/aid.2006.22.321","volume":"22","author":"A. Bonjoch","year":"2006","unstructured":"Bonjoch A, Paredes R, Domingo P, et al. Long-term safety and efficacy of nevirapine-based approaches in HIV type 1-infected patients. AIDS Res Hum Retroviruses 2006; 22: 321\u20139","journal-title":"AIDS Res Hum Retroviruses"},{"key":"BF03256916_CR7","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1586\/14787210.2.3.367","volume":"2","author":"A. Milinkovic","year":"2004","unstructured":"Milinkovic A, Martinez E. Nevirapine in the treatment of HIV. Expert Rev Anti Infect Ther 2004; 2: 367\u201373","journal-title":"Expert Rev Anti Infect Ther"},{"key":"BF03256916_CR8","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1468-1293.2006.00402.x","volume":"7","author":"V. Reliquet","year":"2006","unstructured":"Reliquet V, Allavena C, Francois-Brunet C, et al. Long-term assessment of nevirapine-containing highly active antiretroviral therapy in antiretroviral-naive HIV-infected patients: 3-year follow-up of the VIRGO study. HIV Med 2006; 7: 431\u20136","journal-title":"HIV Med"},{"key":"BF03256916_CR9","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1177\/135965350501000509","volume":"10","author":"E. Ribera","year":"2005","unstructured":"Ribera E, Rodriguez-Pardo D, Rubio M, et al. Efficacy and safety of once-daily combination therapy with didanosine, lamivudine and nevirapine in antiretroviral-naive HIV-infected patients. Antivir Ther 2005; 10: 605\u201314","journal-title":"Antivir Ther"},{"key":"BF03256916_CR10","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1001\/jama.300.5.555","volume":"300","author":"S.M. Hammer","year":"2008","unstructured":"Hammer SM, Eron Jr JJ, Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society\u2014USA Panel. JAMA 2008; 300: 555\u201370","journal-title":"JAMA"},{"key":"BF03256916_CR11","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.2165\/00003495-200666150-00006","volume":"66","author":"B.M. Bergersen","year":"2006","unstructured":"Bergersen BM. Cardiovascular risk in patients with HIV Infection: impact of antiretroviral therapy. Drugs 2006; 66: 1971\u201387","journal-title":"Drugs"},{"issue":"Suppl.1","key":"BF03256916_CR12","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1097\/00126334-200309011-00012","volume":"34","author":"B. Clotet","year":"2003","unstructured":"Clotet B, van der Valk M, Negredo E, et al. Impact of nevirapine on lipid metabolism. J Acquir Immune Defic Syndr 2003; 34Suppl. 1: S79\u201384","journal-title":"J Acquir Immune Defic Syndr"},{"key":"BF03256916_CR13","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/j.1468-1293.2008.00636.x","volume":"9","author":"B.G. Gazzard","year":"2008","unstructured":"Gazzard BG. British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Medicine 2008; 9: 563\u2013608","journal-title":"HIV Medicine"},{"key":"BF03256916_CR14","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1097\/00002030-200005050-00006","volume":"14","author":"P. Barreiro","year":"2000","unstructured":"Barreiro P, Soriano V, Blanco F, et al. Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy. AIDS 2000; 14: 807\u201312","journal-title":"AIDS"},{"key":"BF03256916_CR15","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1310\/EYWJ-8B5K-X7VQ-9CPE","volume":"7","author":"G. Guaraldi","year":"2006","unstructured":"Guaraldi G, Orlando G, Squillace N, et al. Multidisciplinary approach to the treatment of metabolic and morphologic alterations of HIV-related lipodystrophy. HIV Clin Trials 2006; 7: 97\u2013106","journal-title":"HIV Clin Trials"},{"key":"BF03256916_CR16","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.atherosclerosis.2005.11.031","volume":"189","author":"C. Schmidt","year":"2006","unstructured":"Schmidt C, Fagerberg B, Wikstrand J, et al. ApoB\/apoA-I ratio is related to femoral artery plaques and is predictive for future cardiovascular events in healthy men. Atherosclerosis 2006; 189: 178\u201385","journal-title":"Atherosclerosis"},{"key":"BF03256916_CR17","doi-asserted-by":"crossref","first-page":"695","DOI":"10.3346\/jkms.2006.21.4.695","volume":"21","author":"S. Lee","year":"2006","unstructured":"Lee S, Choi S, Kim HJ, et al. Cutoff values of surrogate measures of insulin resistance for metabolic syndrome in Korean non-diabetic adults. J Korean Med Sci 2006; 21: 695\u2013700","journal-title":"J Korean Med Sci"},{"key":"BF03256916_CR18","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1161\/01.CIR.97.18.1876","volume":"97","author":"S.M. Grundy","year":"1998","unstructured":"Grundy SM, Balady GJ, Criqui MH, et al. Primary prevention of coronary heart disease: guidance from Framingham. A statement for healthcare professionals from the AHA Task Force on Risk Reduction. Circulation 1998; 97: 1876\u201387","journal-title":"Circulation"},{"key":"BF03256916_CR19","unstructured":"Grundy SH, D\u2019Agostino RB, Mosca L, et al. Summary of National Heart, Lung, and Blood Institute workshop on cardiovascular risk assessment. National Heart, Lung, and Blood Institute, Bethesda, MD, 2003"},{"key":"BF03256916_CR20","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s11892-009-0008-7","volume":"9","author":"G. Barbaro","year":"2009","unstructured":"Barbaro G, Iacobellis G. Metabolic syndrome associated with HIV and highly active antiretroviral therapy. Curr Diab Rep 2009; 9: 37\u201342","journal-title":"Curr Diab Rep"},{"key":"BF03256916_CR21","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.atherosclerosis.2009.06.011","volume":"208","author":"G. Guaraldi","year":"2010","unstructured":"Guaraldi G, Stentarelli C, Zona S, et al. Lipodystrophy and anti-retroviral therapy as predictors of sub-clinical atherosclerosis in human immunodeficiency virus infected subjects. Atherosclerosis 2010; 208: 222\u20137","journal-title":"Atherosclerosis"},{"key":"BF03256916_CR22","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/j.1365-2362.2004.01379.x","volume":"34","author":"J.M. Petit","year":"2004","unstructured":"Petit JM, Duong M, Masson D, et al. Serum adiponectin and metabolic parameters in HIV-1-infected patients after substitution of nevirapine for protease inhibitors. Eur J Clin Invest 2004; 34: 569\u201375","journal-title":"Eur J Clin Invest"},{"key":"BF03256916_CR23","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1097\/01.aids.0000174451.78497.8f","volume":"19","author":"L. Calza","year":"2005","unstructured":"Calza L, Manfredi R, Colangeli V, et al. Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidaemia. AIDS 2005; 19: 1051\u20138","journal-title":"AIDS"},{"key":"BF03256916_CR24","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1097\/00002030-200207050-00010","volume":"16","author":"E. Negredo","year":"2002","unstructured":"Negredo E, Ribalta J, Paredes R, et al. Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine. AIDS 2002; 16: 1383\u20139","journal-title":"AIDS"},{"key":"BF03256916_CR25","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1097\/00002030-200112070-00008","volume":"15","author":"M. Valk van der","year":"2001","unstructured":"van der Valk M, Kastelein JJ, Murphy RL, et al. Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. AIDS 2001; 15: 2407\u201314","journal-title":"AIDS"},{"key":"BF03256916_CR26","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1177\/135965350501000511","volume":"10","author":"J. Young","year":"2005","unstructured":"Young J, Weber R, Rickenbach M, et al. Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study. Antivir Ther 2005; 10: 585\u201391","journal-title":"Antivir Ther"},{"key":"BF03256916_CR27","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/01.qai.0000143037.70120.fc","volume":"38","author":"R. Manfredi","year":"2005","unstructured":"Manfredi R, Calza L, Chiodo F. An extremely different dysmetabolic profile between the two available non-nucleoside reverse transcriptase inhibitors: efavirenz and nevirapine. J Acquir Immune Defic Syndr 2005; 38: 236\u20138","journal-title":"J Acquir Immune Defic Syndr"},{"key":"BF03256916_CR28","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/00001432-200302000-00004","volume":"16","author":"M. Valk van der","year":"2003","unstructured":"van der Valk M, Reiss P. Lipid profiles associated with antiretroviral drug choices. Curr Opin Infect Dis 2003; 16: 19\u201323","journal-title":"Curr Opin Infect Dis"},{"key":"BF03256916_CR29","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1097\/00002030-199905070-00009","volume":"13","author":"E. Martinez","year":"1999","unstructured":"Martinez E, Conget I, Lozano L, et al. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS 1999; 13: 805\u201310","journal-title":"AIDS"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03256916.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF03256916\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03256916","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T22:05:13Z","timestamp":1688076313000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF03256916"}},"subtitle":["A Cross-Sectional, Observational Study"],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":29,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["BF03256916"],"URL":"https:\/\/doi.org\/10.1007\/bf03256916","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,11]]}}}